

Acute Kidney Injury from Intravitreal Anti-vascular Endothelial Growth Factor Drugs: A Systematic Review and Meta-analysis of Randomized Controlled Trials



Up to February 3, 2023




13 RCTs included



4,282 participants



PROSPERO
CRD42021267854



Main analysis

OR: 1.00 (95% CI: 0.49-2.04)

Subgroup analyses

Aflibercept OR: 1.10 (95% CI: 0.27-4.43)

Ranibizumab OR: 0.97 (95% CI: 0.42-2.22)

AMD OR: 4.61 (95% CI: 0.07-284.13)

DR/DME OR: 0.90 (95% CI: 0.42-1.93)

RVO OR: 1.57 (95% CI: 0.16-15.88)

Conclusion: Intravitreal anti-VEGF drugs were not associated with AKI risk, regardless of which anti-VEGF drugs (aflibercept or ranibizumab) or retinal diseases (AMD, DR/DME or RVO) were involved.